CompletedPhase 2

Anakinra as a Treatment for Hydradenitis Suppurativa

United States6 participantsStarted 2012-10

Plain-language summary

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Use of the following therapies:
✕. history of immunocompromise including HIV infection
✕. positive Hep B surface antigen -

What they're measuring

Change in Modified Sartorius Score

Timeframe: Baseline, 8 weeks

Trial details

NCT IDNCT01516749

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-05

Results submitted2014-07-11

View on ClinicalTrials.gov More Hidradenitis Suppurativa trials